| ISIN | LU0115986761 |
|---|---|
| Valor Number | 1113164 |
| Bloomberg Global ID | |
| Fund Name | RH&P Global Life Sciences Fund A CAP USD |
| Fund Provider |
RH&PARTNER Investment Funds
Basel, Switzerland Phone: +41 61 378 83 63 E-Mail: info@rh-finanz.ch Web: https://www.rh-finanz.ch |
| Fund Provider | RH&PARTNER Investment Funds |
| Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
| Distributor(s) |
Banque Pictet & Cie SA
Credit Suisse Zürich UBS n/a Vontobel n/a |
| Asset Class | Equities |
| EFC Category | Equity Health Care |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
| Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 210.19 USD | 30.12.2025 |
|---|---|---|
| Previous Price * | 213.44 USD | 29.12.2025 |
| 52 Week High * | 217.04 USD | 27.11.2025 |
| 52 Week Low * | 152.05 USD | 08.04.2025 |
| NAV * | 210.19 USD | 30.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 70,719,976 | |
| Unit/Share Assets *** | 65,999,665 | |
| Trading Information SIX | ||
| YTD Performance | +22.71% |
31.12.2024 - 30.12.2025
31.12.2024 30.12.2025 |
|---|---|---|
| YTD Performance (in CHF) | +7.00% |
31.12.2024 - 30.12.2025
31.12.2024 30.12.2025 |
| 1 month | -1.39% |
01.12.2025 - 30.12.2025
01.12.2025 30.12.2025 |
| 3 months | +13.66% |
30.09.2025 - 30.12.2025
30.09.2025 30.12.2025 |
| 6 months | +25.98% |
30.06.2025 - 30.12.2025
30.06.2025 30.12.2025 |
| 1 year | +22.75% |
30.12.2024 - 30.12.2025
30.12.2024 30.12.2025 |
| 2 years | +23.96% |
02.01.2024 - 30.12.2025
02.01.2024 30.12.2025 |
| 3 years | +21.22% |
30.12.2022 - 30.12.2025
30.12.2022 30.12.2025 |
| 5 years | +5.12% |
30.12.2020 - 30.12.2025
30.12.2020 30.12.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Charles River Laboratories International Inc | 4.53% | |
|---|---|---|
| Bio-Techne Corp | 4.46% | |
| Nektar Therapeutics | 4.36% | |
| Illumina Inc | 3.93% | |
| Exelixis Inc | 3.87% | |
| Alkermes PLC | 3.72% | |
| IQVIA Holdings Inc | 3.65% | |
| Biogen Inc | 3.59% | |
| Amgen Inc | 3.57% | |
| Incyte Corp | 3.53% | |
| Last data update | 30.04.2021 | |
| TER *** | 2.346% |
|---|---|
| TER date *** | 31.08.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.40% |
| Ongoing Charges *** | 2.43% |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |